Pinealon.
Pinealon is a synthetic ultrashort tripeptide with the sequence glutamic acid–aspartic acid–arginine (Glu-Asp-Arg, abbreviated EDR).
Pinealon is a synthetic ultrashort tripeptide with the sequence glutamic acid–aspartic acid–arginine (Glu-Asp-Arg, abbreviated EDR). Pinealon is research / preclinical, and PepCue grades its published evidence F tier (12/100). This is a research reference, not medical or dosing advice.
What it is
Pinealon is a synthetic ultrashort tripeptide with the sequence glutamic acid–aspartic acid–arginine (Glu-Asp-Arg, abbreviated EDR). It belongs to the class of "peptide bioregulators" developed in Russia by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, who designed short peptides intended to mirror regulatory sequences associated with the pineal gland. It is a research chemical, not an approved drug.
How it works
The proposed mechanism, advanced primarily by the Khavinson group, is that short peptides like EDR penetrate cell and nuclear membranes and interact directly with DNA and chromatin to act as epigenetic modulators of gene expression and protein synthesis. In cell and biophysical studies the EDR peptide has been reported to bind deoxyribooligonucleotides/DNA and to enter the nucleus of HeLa cells, and proposed downstream effects include reduced reactive oxygen species, modulation of MAPK/ERK signaling, lowered pro-apoptotic markers (caspase-3, p53), increased antioxidant enzymes (SOD2, GPX1), and stimulation of serotonin-related (tryptophan hydroxylase) expression in cortical neurons. These are mechanistic hypotheses derived largely from in vitro and computational/biophysical work rather than from established receptor pharmacology.
Mechanism pathways
Short peptides hypothesized to enter cells and influence tissue-specific gene expression.
This group is defined by a shared hypothesis rather than a shared receptor, and the hypothesis is what makes it unusual. The peptide bioregulator concept originated in a single research programme in Russia beginning in the 1970s, initially with peptide extracts prepared from animal organs and later with very short synthetic peptides, typically two to four amino acids, said to reproduce the extracts' activity. The proposal is that these peptides are small enough to cross both the cell membrane and the nuclear envelope without a dedicated transporter, bind directly to DNA promoter regions or to histones, alter chromatin accessibility, and thereby switch on genes that have become silenced with age. Each peptide is claimed to be tissue-specific, acting on the organ its parent extract came from, so a thymus-derived preparation is proposed to act on immune tissue, a pineal-derived one on the pineal gland, and so on. Supporting observations cited by the originating group include reports that some of these peptides bind oligonucleotides in biophysical assays, that fluorescently labelled versions enter the nuclei of cultured cells, and that microarray studies show altered gene expression in treated animal tissues. Reported downstream effects vary by peptide and include changes in immune cell populations, antioxidant enzyme expression, apoptosis markers, and neurotransmitter-related gene expression. The honest assessment must be direct, because this pathway is unusually vulnerable to overstatement. Almost all of the mechanistic and outcome evidence originates from the same laboratory and its close collaborators, published substantially in Russian-language or low-circulation journals, and it has not been independently replicated by unaffiliated groups. Sequence-specific DNA binding by a two-, three-, or four-residue peptide is chemically difficult to reconcile with what is known about how transcription factors achieve specificity, since recognition of a unique genomic site generally requires a much larger binding surface. Longevity and health claims attached to these compounds frequently rest on studies that were not blinded, not randomised, or not controlled, and that were conducted by the same group that developed the products. None of these compounds is an approved medicine in the United States, the European Union, or the United Kingdom, though some have regulatory status in Russia and neighbouring countries. Material sold internationally is unregulated. The proposed mechanism should be understood as an unconfirmed hypothesis, not an established pathway.
The evidence
There are no completed human efficacy trials of pinealon; the evidence base is preclinical (in vitro cell culture, biophysical, and rodent) and clusters heavily around a single research lineage. Reported findings include increased neuronal cell viability and suppression of free radicals in culture (Khavinson, Rejuvenation Research 2011), nuclear penetration and DNA binding of fluorescently labeled short peptides (Fedoreyeva, Biochemistry Moscow 2011), stimulation of serotonin expression in brain cortex cells (Khavinson, Bull Exp Biol Med 2014), and antioxidant/neuroprotective effects in aged-rat hypoxia and carotid-occlusion models (Mendzheritsky, Adv Gerontol 2011, 2014). A 2020 Molecules review by the developers frames EDR as a candidate neuroprotective agent for early Alzheimer's disease, but it is a hypothesis-generating review of the group's own animal and in vitro data, not clinical proof. Independent, non-affiliated replication is essentially absent, so reported effects should be treated as preliminary.
The evidence, in brief
A synthetic tripeptide (Glu-Asp-Arg / EDR), one of the Russian “peptide bioregulators” proposed to modulate neuroprotective gene expression. Reported effects derive almost entirely from preclinical work and small Russian-language studies; rigorous, independently replicated human trials are lacking.
- EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation in Alzheimer's DiseaseMolecules, 2020 (PMID 33396470)
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #051
Little indexed evidence or largely speculative.
Mostly online reports, no real study base yet.
Claim receipts
Popular claims about Pinealon, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
Neuroprotective findings come from cell culture and rodent hypoxia models clustered around a single research lineage, with essentially no independent replication.
The DNA and chromatin interaction is a mechanistic hypothesis from in vitro and biophysical work by the originating group, not established receptor pharmacology.
The supporting publication is a hypothesis-generating review of the developers' own animal and in vitro data, with no human efficacy trial.
There are no published controlled human safety or pharmacokinetic studies, and research-chemical vials have unverified identity, purity and sterility.
Safety profile
Documented safety data in humans are effectively nonexistent; there are no published controlled human safety or pharmacokinetic trials, and no established toxicology dossier in the peer-reviewed literature. Materials sold as "pinealon" are research chemicals not manufactured to pharmaceutical GMP standards, so identity, purity, sterility, and endotoxin content are unverified and vary by vendor. Long-term effects, immunogenicity, and any consequences of the proposed DNA-interacting mechanism are unstudied in humans. Because the compound is unapproved and unregulated for human use, its risk profile is genuinely unknown rather than established as safe.
Compound notes
- Pinealon is a short synthetic peptide bioregulator (Glu-Asp-Arg) from the Khavinson peptide-bioregulator line, marketed for brain/cognition.
- Rigorous independent evidence is minimal.
- Not FDA-approved; research-only.
- Cognitive/anti-aging claims are not established in robust trials.
Regulatory status
Pinealon is not approved by the FDA or, to public knowledge, any major regulatory authority; it has no ATC code and no standard pharmaceutical identifiers (DrugBank/KEGG/UNII), and is sold only as a research-use-only chemical. It is not a recognized therapeutic and is not WADA-listed as a named substance, though related growth/peptide categories may fall under broader anti-doping provisions.
Sold research-use-only; human evidence is limited or preclinical.
By the numbers
- 01Synthetic tripeptide Glu-Asp-Arg (EDR), one of the Khavinson-group 'peptide bioregulators'
- 02Associated conceptually with the pineal gland, the source of its name
- 03Evidence is preclinical only (in vitro, biophysical, rodent) with no completed human trials
- 04Proposed to act epigenetically by directly interacting with DNA/chromatin rather than via a classical receptor
- 05Research is dominated by a single affiliated group with little independent replication
- 06Has no ATC code and no DrugBank/KEGG/UNII identifiers; research-use-only status
Pinealon: research formats
Choose the format you are researching to see route-specific notes.
A Khavinson short peptide bioregulator with no completed human trials, so no human format exists.
Pinealon is the synthetic tripeptide Glu-Asp-Arg, one of the short peptide bioregulators developed by the Khavinson group in St. Petersburg. The published evidence is in vitro, biophysical, and rodent, with no completed human trials, so nothing establishes a human route or schedule. This page presents no example concentration math.
Research on this family of peptides is dominated by a single affiliated group with little independent replication, which is the main reason to treat the absence of a human format as a real gap rather than a paperwork one.
Pinealon has no ATC code and no DrugBank, KEGG, or UNII identifiers, and is sold only as a research-use-only chemical.
Sources
Every factual claim above resolves to a real, published source.
- Pinealon Increases Cell Viability by Suppression of Free Radical Levels and Activating Proliferative ProcessesRejuvenation Research, 2011, PMID 21978084
- EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's DiseaseMolecules, 2020, PMID 33396470
- Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNABiochemistry (Moscow), 2011, PMID 22117547
- Short peptides stimulate serotonin expression in cells of brain cortexBulletin of Experimental Biology and Medicine, 2014, PMID 24909721
Cite this page
PepCue. “Pinealon: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/pinealon.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.